IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Boehringer Ingelheim is a Proprietary Company that generates the majority of its income from the Pharmaceuticals Wholesaling industry. In 2024 the company generated total revenue of $385,233,000 including sales and other revenue. In 2024 Boehringer Ingelheim had 228 employees including employees from all subsidiaries under the company's control. The Chief Executive of Boehringer Ingelheim is Mr Wesley Cook whose official title is Managing Director. The Chairman of Boehringer Ingelheim is either not applicable or not available. Boehringer Ingelheim is primarily involved with researching, developing, manufacturing and marketing pharmaceutical and chemical products. The company focuses on the following areas Human Health: Metabolic Diseases Cancer Lung Diseas Skin Disease Mental Disorders Retinal Diseases Human Health ProductsAnimal Health: Companion Animals Vetinary Public Health Livestock Animal Health Products
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Boehringer Ingelheim Pty Limited includes market sizing, forecasting, data and analysis. The most recent publication will be as current as of March 2026.
Boehringer Ingelheim Pty Limited, trading as Boehringer Ingelheim, operates under the ABN 52 000 452 308 and was incorporated on 24 March 1964. Boehringer Ingelheim Pty Limited primarily operates in the Pharmaceuticals Wholesaling industry in Australia.
The Key Personnel chapter outlines the principal leadership positions within Boehringer Ingelheim Pty Limited, including the Chairman, Board members, Chief Executive Officer, and other key management personnel. It provides an overview of the company’s governance and executive structure, along with a breakdown of gender diversity across leadership roles, offering insight into the composition of the organisation’s senior team.
The Financials chapter presents Boehringer Ingelheim Pty Limited’s historical financial performance, including detailed profit and loss statements outlining sales revenue, cost of sales, and profitability. It also incorporates balance sheet data, providing a breakdown of assets and liabilities, as well as additional financial metrics such as the number of shares on issue. Together, these disclosures offer a comprehensive view of the company’s financial position and performance over time.
The Growth & Ratios chapter provides historical data on key financial performance indicators, enabling an assessment of the company’s operational efficiency, profitability, and financial structure over time. Metrics covered include return on equity, return on assets, profit margins, revenue per employee, as well as gearing and leverage ratios, offering a comprehensive view of performance trends and capital management.
The Operating Segments chapter provides an overview of the revenue composition and asset allocation across the various industries in which Boehringer Ingelheim Pty Limited operates. It offers insights into how the company’s financial performance is distributed among its core business segments, highlighting the relative contribution of each industry to total revenue.
The Competitor Benchmarking chapter includes a comparative assessment of Boehringer Ingelheim Pty Limited’s key financial, growth, and valuation ratios against industry averages to evaluate its competitive position. It analyses valuation metrics such as price-to-earnings, price-to-book, enterprise value to EBITDA, and enterprise value to sales, alongside core financial indicators including liquidity ratios and profitability measures.
The Shareholders chapter provides a breakdown of the ownership structure of Boehringer Ingelheim Pty Limited, identifying key shareholders and outlining their respective ownership interests. This section offers insight into the concentration of shareholdings, the presence of institutional or strategic investors, and the overall distribution of equity within the company.
The Subsidiaries chapter provides an overview of the companies and business entities that are wholly or partially owned by Boehringer Ingelheim Pty Limited. It outlines the ownership structure of each subsidiary, offering insight into the broader corporate group and how these entities contribute to the company’s overall activities and performance.
The History chapter presents a overview of Boehringer Ingelheim Pty Limited’s development, highlighting key milestones and significant corporate events since its incorporation. It includes the company’s incorporation date and outlines major strategic, operational, and structural developments, providing context for its evolution and current market position.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
Boehringer Ingelheim is primarily involved with researching, developing, manufacturing and marketing pharmaceutical and chemical products. The company focuses on the following areas Human Health: Metabolic Diseases Cancer Lung Diseas Skin Disease Mental Disorders Retinal Diseases Human Health ProductsAnimal Health: Companion Animals Vetinary Public Health Livestock Animal Health Products
Boehringer Ingelheim Pty Limited, trading as Boehringer Ingelheim, is a Private Company that generates the majority of its income from the Pharmaceuticals Wholesaling industry in Australia.
Murray Cod Australia Limited company is based at 78 Waterloo Road, Macquarie park, New South Wales, Australia.
The DIRECTOR of Boehringer Ingelheim Pty Limited is Adam Papadakis and the DIRECTOR is Xiomara Sandoval Escobar.
In 2025, Boehringer Ingelheim Pty Limited generated total revenue of approximately $385.2 million.